7436-07-9Relevant articles and documents
Asymmetric Cross [10+2] Cycloadditions of 2-Alkylidene-1-indanones and Activated Alkenes under Phase-Transfer Catalysis
Yang, Yang,Jiang, Ying,Du, Wei,Chen, Ying-Chun
supporting information, p. 1754 - 1758 (2020/02/11)
Isobenzofulvene species are versatile synthons in organic chemistry, which have been employed in diverse challenging higher-order cycloaddition reactions. Here, the first chemoselective and asymmetric cross [10+2] cycloaddition reaction between activated 2-alkylidene-1-indanones and a variety of electron-deficient alkenes has been developed, relying on the in situ generation of dearomative 1-hydroxyl isobenzofulvene anion intermediates under the catalysis of a newly designed bulky cinchona-derived phase-transfer compound. An array of fused frameworks with multifunctionalities were generally furnished in excellent diastereo- and enantioselectivity, even at 1 mol % catalyst loadings.
Novel sulfamoyl benzamides as selective CB2 agonists with improved in vitro metabolic stability
Sellitto, Ian,Bourdonnec, Bertrand Le,Worm, Karin,Goodman, Allan,Savolainen, Markku A.,Chu, Guo-Hua,Ajello, Christopher W.,Saeui, Christopher T.,Leister, Lara K.,Cassel, Joel A.,DeHaven, Robert N.,LaBuda, Christopher J.,Koblish, Michael,Little, Patrick J.,Brogdon, Bernice L.,Smith, Steven A.,Dolle, Roland E.
scheme or table, p. 387 - 391 (2010/04/06)
A lead optimization campaign in our previously reported sulfamoyl benzamide class of CB2 agonists was conducted to improve the in vitro metabolic stability profile in this series while retaining high potency and selectivity for the CB2 receptor. From this study, compound 14, N-(3,4-dimethyl-5-(morpholinosulfonyl)phenyl)-2,2-dimethylbutanamide, was identified as a potent and selective CB2 agonist exhibiting moderate in vitro metabolic stability and oral bioavailability. Compound 14 demonstrated in vivo efficacy in a rat model of post-surgical pain.
